Proliferative Vitreoretinopathy PVR-Pipeline Review, H1 2016

Proliferative Vitreoretinopathy PVR-Pipeline Review, H1 2016


  • Products Id :- GMDHC7799IDB
  • |
  • Pages: 40
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Proliferative Vitreoretinopathy (PVR)-Pipeline Review, H1 2016', provides an overview of the Proliferative Vitreoretinopathy (PVR) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR)

The report reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Proliferative Vitreoretinopathy (PVR) therapeutics and enlists all their major and minor projects

The report assesses Proliferative Vitreoretinopathy (PVR) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (PVR)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Proliferative Vitreoretinopathy (PVR)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Proliferative Vitreoretinopathy (PVR) Overview 6

Therapeutics Development 7

Pipeline Products for Proliferative Vitreoretinopathy (PVR)-Overview 7

Pipeline Products for Proliferative Vitreoretinopathy (PVR)-Comparative Analysis 8

Proliferative Vitreoretinopathy (PVR)-Therapeutics under Development by Companies 9

Proliferative Vitreoretinopathy (PVR)-Therapeutics under Investigation by Universities/Institutes 10

Proliferative Vitreoretinopathy (PVR)-Pipeline Products Glance 11

Early Stage Products 11

Proliferative Vitreoretinopathy (PVR)-Products under Development by Companies 12

Proliferative Vitreoretinopathy (PVR)-Products under Investigation by Universities/Institutes 13

Proliferative Vitreoretinopathy (PVR)-Companies Involved in Therapeutics Development 14

Novartis AG 14

Promedior, Inc. 15

RXi Pharmaceuticals Corporation 16

Proliferative Vitreoretinopathy (PVR)-Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 23

Drug Profiles 25

Drug to Inhibit TAK1 for Proliferative Vitreoretinopathy-Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

LD-224-Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

PRM-167-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

RNAi Oligonucleotide to Inhibit CTGF for PVR-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

XOMA-089-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Proliferative Vitreoretinopathy (PVR)-Recent Pipeline Updates 31

Proliferative Vitreoretinopathy (PVR)-Dormant Projects 33

Proliferative Vitreoretinopathy (PVR)-Product Development Milestones 34

Featured News & Press Releases 34

Apr 27, 2015: RXi Pharmaceuticals Announces Upcoming Presentations at Leading Partnering and Scientific Conferences 34

May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform 35

May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering Technology Platform 36

May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 36

May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 37

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Figures

Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H1 2016 7

Number of Products under Development for Proliferative Vitreoretinopathy (PVR)-Comparative Analysis, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Early Stage Products, H1 2016 11

Assessment by Monotherapy Products, H1 2016 17

Number of Products by Targets, H1 2016 18

Number of Products by Stage and Targets, H1 2016 18

Number of Products by Mechanism of Actions, H1 2016 20

Number of Products by Stage and Mechanism of Actions, H1 2016 20

Number of Products by Molecule Types, H1 2016 23

Number of Products by Stage and Molecule Types, H1 2016 23

List of Tables

Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H1 2016 7

Number of Products under Development for Proliferative Vitreoretinopathy (PVR)-Comparative Analysis, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Number of Products under Investigation by Universities/Institutes, H1 2016 10

Comparative Analysis by Early Stage Development, H1 2016 11

Products under Development by Companies, H1 2016 12

Products under Investigation by Universities/Institutes, H1 2016 13

Proliferative Vitreoretinopathy (PVR)-Pipeline by Novartis AG, H1 2016 14

Proliferative Vitreoretinopathy (PVR)-Pipeline by Promedior, Inc., H1 2016 15

Proliferative Vitreoretinopathy (PVR)-Pipeline by RXi Pharmaceuticals Corporation, H1 2016 16

Assessment by Monotherapy Products, H1 2016 17

Number of Products by Stage and Target, H1 2016 19

Number of Products by Stage and Mechanism of Action, H1 2016 21

Number of Products by Stage and Route of Administration, H1 2016 22

Number of Products by Stage and Molecule Type, H1 2016 24

Proliferative Vitreoretinopathy (PVR) Therapeutics-Recent Pipeline Updates, H1 2016 31

Proliferative Vitreoretinopathy (PVR)-Dormant Projects, H1 2016 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Novartis AG

Promedior, Inc.

RXi Pharmaceuticals Corporation

Proliferative Vitreoretinopathy (PVR) Therapeutic Products under Development, Key Players in Proliferative Vitreoretinopathy (PVR) Therapeutics, Proliferative Vitreoretinopathy (PVR) Pipeline Overview, Proliferative Vitreoretinopathy (PVR) Pipeline, Proliferative Vitreoretinopathy (PVR) Pipeline Assessment

select a license

Single User License
USD 2000 INR 128960
Site License
USD 4000 INR 257920
Corporate User License
USD 6000 INR 386880

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com